Jpmorgan Chase & CO Tekla Life Sciences Investors Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Tekla Life Sciences Investors stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2 shares of HQL stock, worth $26. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$26
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HQL
# of Institutions
77Shares Held
9.31MCall Options Held
0Put Options Held
0-
Saba Capital Management, L.P. New York, NY3.43MShares$45.1 Million1.1% of portfolio
-
Penserra Capital Management LLC Orinda, CA776KShares$10.2 Million0.25% of portfolio
-
Morgan Stanley New York, NY490KShares$6.43 Million0.0% of portfolio
-
Karpus Management, Inc. Pittsford, NY469KShares$6.16 Million0.23% of portfolio
-
Sit Investment Associates Inc Minneapolis, MN417KShares$5.48 Million0.14% of portfolio
About TEKLA LIFE SCIENCES INVESTORS
- Ticker HQL
- Exchange NYSE
- Sector Financial Services
- Industry Asset Management
- Description
- Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...